
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Passage Bio Inc (PASG)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PASG (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $59.25
1 Year Target Price $59.25
5 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.75% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.38M USD | Price to earnings Ratio 0.18 | 1Y Target Price 59.25 |
Price to earnings Ratio 0.18 | 1Y Target Price 59.25 | ||
Volume (30-day avg) 5 | Beta 1.81 | 52 Weeks Range 5.12 - 26.60 | Updated Date 08/28/2025 |
52 Weeks Range 5.12 - 26.60 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 39.4 |
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.202 | Actual -2.96 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.2% | Return on Equity (TTM) -88.27% |
Valuation
Trailing PE 0.18 | Forward PE - | Enterprise Value -10516882 | Price to Sales(TTM) - |
Enterprise Value -10516882 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.87 | Shares Outstanding 3178710 | Shares Floating 2867165 |
Shares Outstanding 3178710 | Shares Floating 2867165 | ||
Percent Insiders 0.21 | Percent Institutions 54.51 |
Upturn AI SWOT
Passage Bio Inc

Company Overview
History and Background
Passage Bio, Inc. (PASG) was founded in 2017 and focused on developing gene therapies for central nervous system disorders. It faced challenges and ultimately underwent a strategic restructuring and reverse merger.
Core Business Areas
- Gene Therapy Development (Historical): Passage Bio previously focused on developing AAV-delivered gene therapies for rare, monogenic CNS diseases. This was the core of their operations before restructuring.
- Transferred Technology Assets: In 2023, Passage Bio divested a majority of its pre-clinical AAV-based gene therapy technology assets and related personnel and infrastructure to a new private biotechnology company called Synnovation Bio.
Leadership and Structure
Prior to its restructuring, Passage Bio had a typical biotech leadership team (CEO, CSO, etc.). Following the reverse merger, the leadership reflects that of the acquiring company.
Top Products and Market Share
Key Offerings
- PBGM01 (historical): An AAV-delivered gene therapy for GM1 gangliosidosis. Development has been discontinued following their restructuring. Market share: Not applicable. Competitors: Before the discontinuation, competitors included companies developing similar gene therapies for lysosomal storage disorders.
Market Dynamics
Industry Overview
The gene therapy market is highly competitive and rapidly evolving. It involves significant regulatory hurdles and substantial investment in R&D. It now focuses on cell therapies, and biologics for treating chronic diseases. The industry is marked by high risk and potential high reward.
Positioning
Passage Bio, post-restructuring, now operates in a different capacity, primarily focused on managing its remaining assets and exploring new opportunities following the reverse merger. Their previous positioning as a gene therapy developer is no longer accurate.
Total Addressable Market (TAM)
The total addressable market for gene therapies addressing rare CNS disorders was estimated in the billions of dollars. Passage Bio's position relative to that TAM is now significantly reduced given the terminated programs and the reverse merger.
Upturn SWOT Analysis
Strengths
- Cash reserves from previous funding rounds
- Experienced management team during previous operations
- Intellectual property related to AAV gene therapy (now transferred)
Weaknesses
- Discontinued development programs
- Lack of revenue-generating products
- Uncertainty about future strategic direction
- Negative publicity from restructuring
Opportunities
- Strategic partnerships or acquisitions
- Repurposing existing assets
- Entering new therapeutic areas
Threats
- Competition from established biotech companies
- Regulatory hurdles for gene therapies
- Financial instability
- Market volatility
- Uncertainty about regulatory landscape
Competitors and Market Share
Key Competitors
- BLUE
- AVRO
- SGMO
Competitive Landscape
Passage Bio's competitive position was weakened by the discontinued programs. The merged entity now faces a new competitive landscape depending on its chosen area of focus.
Growth Trajectory and Initiatives
Historical Growth: Prior to the restructuring, Passage Bio experienced growth in terms of research and development spending, clinical trials initiation, and headcount. This growth has ceased.
Future Projections: Future projections are speculative and depend on the new direction of the merged entity.
Recent Initiatives: The most significant recent initiative was the strategic restructuring, the technology transfer to Synnovation Bio, and reverse merger to a new target
Summary
Passage Bio faced significant challenges, leading to a strategic restructuring, the divestiture of its gene therapy technology assets, and a reverse merger. Its previous business model focused on gene therapies for rare CNS disorders but its programs were discontinued. The company's future depends on the strategic direction of the new entity formed from the reverse merger. Investors should carefully evaluate any new business plans and assess the associated risks and opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports (historical)
- Market Research Reports (historical)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The financial data and analysis are based on publicly available information and may not be entirely accurate or complete. Investing in biotech companies involves significant risks, including the risk of loss of capital.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Passage Bio Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2020-02-28 | President, CEO & Director Dr. William Chou M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.passagebio.com |
Full time employees 60 | Website https://www.passagebio.com |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.